Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1999 Sep;67(3):290–299. doi: 10.1136/jnnp.67.3.290

Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil"

B M van Geel 1, J Assies 1, E Haverkort 1, J Koelman 1, B Verbeeten 1, R Wanders 1, P Barth 1
PMCID: PMC1736534  PMID: 10449548

Full Text

The Full Text of this article is available as a PDF (185.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aalfs C. M., Koelman J. H., Posthumus Meyjes F. E., Ongerboer de Visser B. W. Posterior tibial and sural nerve somatosensory evoked potentials: a study in spastic paraparesis and spinal cord lesions. Electroencephalogr Clin Neurophysiol. 1993 Dec;89(6):437–441. doi: 10.1016/0168-5597(93)90118-9. [DOI] [PubMed] [Google Scholar]
  2. Aramideh M., Hoogendijk J. E., Aalfs C. M., Posthumus Meyjes F. E., De Visser M., Ongerboer de Visser B. W. Somatosensory evoked potentials, sensory nerve potentials and sensory nerve conduction in hereditary motor and sensory neuropathy type I. J Neurol. 1992 May;239(5):277–283. doi: 10.1007/BF00810353. [DOI] [PubMed] [Google Scholar]
  3. Asano J., Suzuki Y., Yajima S., Inoue K., Shimozawa N., Kondo N., Murase M., Orii T. Effects of erucic acid therapy on Japanese patients with X-linked adrenoleukodystrophy. Brain Dev. 1994 Nov-Dec;16(6):454–458. doi: 10.1016/0387-7604(94)90007-8. [DOI] [PubMed] [Google Scholar]
  4. Assies J., Gooren L. J., Van Geel B., Barth P. G. Signs of testicular insufficiency in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy: a retrospective study. Int J Androl. 1997 Oct;20(5):315–321. doi: 10.1046/j.1365-2605.1997.00066.x. [DOI] [PubMed] [Google Scholar]
  5. Aubourg P., Adamsbaum C., Lavallard-Rousseau M. C., Rocchiccioli F., Cartier N., Jambaqué I., Jakobezak C., Lemaitre A., Boureau F., Wolf C. A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy. N Engl J Med. 1993 Sep 9;329(11):745–752. doi: 10.1056/NEJM199309093291101. [DOI] [PubMed] [Google Scholar]
  6. Aubourg P., Blanche S., Jambaqué I., Rocchiccioli F., Kalifa G., Naud-Saudreau C., Rolland M. O., Debré M., Chaussain J. L., Griscelli C. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med. 1990 Jun 28;322(26):1860–1866. doi: 10.1056/NEJM199006283222607. [DOI] [PubMed] [Google Scholar]
  7. Brown F. R., 3rd, Van Duyn M. A., Moser A. B., Schulman J. D., Rizzo W. B., Snyder R. D., Murphy J. V., Kamoshita S., Migeon C. J., Moser H. W. Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Med J. 1982 Oct;151(4):164–172. [PubMed] [Google Scholar]
  8. Cappa M., Bertini E., del Balzo P., Cambiaso P., Di Biase A., Salvati S. High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry. 1994 Nov;57 (Suppl):69–71. doi: 10.1136/jnnp.57.suppl.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kemp S., Wei H. M., Lu J. F., Braiterman L. T., McGuinness M. C., Moser A. B., Watkins P. A., Smith K. D. Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med. 1998 Nov;4(11):1261–1268. doi: 10.1038/3242. [DOI] [PubMed] [Google Scholar]
  10. Konijnenberg A., van Geel B. M., Sturk A., Schaap M. C., von dem Borne A. E., de Bruijne-Admiraal L. G., Schutgens R. B., Assies J., Barth P. G. Lorenzo's oil and platelet activation in adrenomyeloneuropathy and asymptomatic X-linked adrenoleukodystrophy. Platelets. 1998;9(1):41–48. doi: 10.1080/09537109876997. [DOI] [PubMed] [Google Scholar]
  11. Korenke G. C., Christen H. J., Kruse B., Hunneman D. H., Hanefeld F. Progression of X-linked adrenoleukodystrophy under interferon-beta therapy. J Inherit Metab Dis. 1997 Mar;20(1):59–66. doi: 10.1023/a:1005361607523. [DOI] [PubMed] [Google Scholar]
  12. Korenke G. C., Hunneman D. H., Kohler J., Stöckler S., Landmark K., Hanefeld F. Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X-chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: effect on clinical, biochemical and neurophysiological parameters. Eur J Pediatr. 1995 Jan;154(1):64–70. doi: 10.1007/BF01972976. [DOI] [PubMed] [Google Scholar]
  13. Korenke G. C., Roth C., Krasemann E., Hüfner M., Hunneman D. H., Hanefeld F. Variability of endocrinological dysfunction in 55 patients with X-linked adrenoleucodystrophy: clinical, laboratory and genetic findings. Eur J Endocrinol. 1997 Jul;137(1):40–47. doi: 10.1530/eje.0.1370040. [DOI] [PubMed] [Google Scholar]
  14. Krivit W., Lockman L. A., Watkins P. A., Hirsch J., Shapiro E. G. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inherit Metab Dis. 1995;18(4):398–412. doi: 10.1007/BF00710052. [DOI] [PubMed] [Google Scholar]
  15. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  16. Lazo O., Contreras M., Hashmi M., Stanley W., Irazu C., Singh I. Peroxisomal lignoceroyl-CoA ligase deficiency in childhood adrenoleukodystrophy and adrenomyeloneuropathy. Proc Natl Acad Sci U S A. 1988 Oct;85(20):7647–7651. doi: 10.1073/pnas.85.20.7647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lu J. F., Lawler A. M., Watkins P. A., Powers J. M., Moser A. B., Moser H. W., Smith K. D. A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9366–9371. doi: 10.1073/pnas.94.17.9366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Moser A. B., Borel J., Odone A., Naidu S., Cornblath D., Sanders D. B., Moser H. W. A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann Neurol. 1987 Mar;21(3):240–249. doi: 10.1002/ana.410210305. [DOI] [PubMed] [Google Scholar]
  19. Moser H. W., Borel J. Dietary management of X-linked adrenoleukodystrophy. Annu Rev Nutr. 1995;15:379–397. doi: 10.1146/annurev.nu.15.070195.002115. [DOI] [PubMed] [Google Scholar]
  20. Moser H. W. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol. 1995 Sep;54(5):740–745. doi: 10.1097/00005072-199509000-00017. [DOI] [PubMed] [Google Scholar]
  21. Moser H. W., Moser A. B., Frayer K. K., Chen W., Schulman J. D., O'Neill B. P., Kishimoto Y. Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology. 1981 Oct;31(10):1241–1249. doi: 10.1212/wnl.31.10.1241. [DOI] [PubMed] [Google Scholar]
  22. Moser H. W., Moser A. B., Kawamura N., Murphy J., Suzuki K., Schaumburg H., Kishimoto Y. Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts. Ann Neurol. 1980 Jun;7(6):542–549. doi: 10.1002/ana.410070607. [DOI] [PubMed] [Google Scholar]
  23. Moser H. W., Moser A. B., Smith K. D., Bergin A., Borel J., Shankroff J., Stine O. C., Merette C., Ott J., Krivit W. Adrenoleukodystrophy: phenotypic variability and implications for therapy. J Inherit Metab Dis. 1992;15(4):645–664. doi: 10.1007/BF01799621. [DOI] [PubMed] [Google Scholar]
  24. Naidu S., Bresnan M. J., Griffin D., O'Toole S., Moser H. W. Childhood adrenoleukodystrophy. Failure of intensive immunosuppression to arrest neurologic progression. Arch Neurol. 1988 Aug;45(8):846–848. doi: 10.1001/archneur.1988.00520320032011. [DOI] [PubMed] [Google Scholar]
  25. Padgett D. A., Loria R. M. In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol, and androstenetriol. J Immunol. 1994 Aug 15;153(4):1544–1552. [PubMed] [Google Scholar]
  26. Poulos A., Gibson R., Sharp P., Beckman K., Grattan-Smith P. Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo's oil. Ann Neurol. 1994 Nov;36(5):741–746. doi: 10.1002/ana.410360509. [DOI] [PubMed] [Google Scholar]
  27. Powers J. M. Adreno-leukodystrophy (adreno-testiculo-leukomyelo-neuropathic-complex). Clin Neuropathol. 1985 Sep-Oct;4(5):181–199. [PubMed] [Google Scholar]
  28. Powers J. M., Liu Y., Moser A. B., Moser H. W. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol. 1992 Nov;51(6):630–643. doi: 10.1097/00005072-199211000-00007. [DOI] [PubMed] [Google Scholar]
  29. Rasmussen M., Moser A. B., Borel J., Khangoora S., Moser H. W. Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo's oil). Neurochem Res. 1994 Aug;19(8):1073–1082. doi: 10.1007/BF00968719. [DOI] [PubMed] [Google Scholar]
  30. Rizzo W. B., Leshner R. T., Odone A., Dammann A. L., Craft D. A., Jensen M. E., Jennings S. S., Davis S., Jaitly R., Sgro J. A. Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology. 1989 Nov;39(11):1415–1422. doi: 10.1212/wnl.39.11.1415. [DOI] [PubMed] [Google Scholar]
  31. Rizzo W. B., Phillips M. W., Dammann A. L., Leshner R. T., Jennings S. S., Avigan J., Proud V. K. Adrenoleukodystrophy: dietary oleic acid lowers hexacosanoate levels. Ann Neurol. 1987 Mar;21(3):232–239. doi: 10.1002/ana.410210304. [DOI] [PubMed] [Google Scholar]
  32. Rizzo W. B., Watkins P. A., Phillips M. W., Cranin D., Campbell B., Avigan J. Adrenoleukodystrophy: oleic acid lowers fibroblast saturated C22-26 fatty acids. Neurology. 1986 Mar;36(3):357–361. doi: 10.1212/wnl.36.3.357. [DOI] [PubMed] [Google Scholar]
  33. Sedlmayr P., Plecko B., Paschke E., Zenz W., Ramschak H., Toplak H., Wascher T. C., Wilders-Truschnig M., Stöckler S. Severely depressed natural killer cell activity of patients with adrenoleukodystrophy under treatment with Lorenzo's oil. J Inherit Metab Dis. 1995;18(1):101–102. doi: 10.1007/BF00711394. [DOI] [PubMed] [Google Scholar]
  34. Singh I., Khan M., Key L., Pai S. Lovastatin for X-linked adrenoleukodystrophy. N Engl J Med. 1998 Sep 3;339(10):702–703. doi: 10.1056/NEJM199809033391012. [DOI] [PubMed] [Google Scholar]
  35. Singh I., Moser A. E., Goldfischer S., Moser H. W. Lignoceric acid is oxidized in the peroxisome: implications for the Zellweger cerebro-hepato-renal syndrome and adrenoleukodystrophy. Proc Natl Acad Sci U S A. 1984 Jul;81(13):4203–4207. doi: 10.1073/pnas.81.13.4203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stumpf D. A., Hayward A., Haas R., Frost M., Schaumburg H. H. Adrenoleukodystrophy. Failure of immunosuppression to prevent neurological progression. Arch Neurol. 1981 Jan;38(1):48–49. doi: 10.1001/archneur.1981.00510010074014. [DOI] [PubMed] [Google Scholar]
  37. Toplak H., Wascher T. C., Pleschko B., Ramschak H., Sedlmayr P., Wilders-Truschnigg M., Stöckler S. Reduced stimulability of platelet surface adhesion molecules under treatment with Lorenzo's oil. J Inherit Metab Dis. 1994;17(5):628–629. doi: 10.1007/BF00711605. [DOI] [PubMed] [Google Scholar]
  38. Tsuji S., Sano T., Ariga T., Miyatake T. Increased synthesis of hexacosanoic acid (C23:0) by cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN). J Biochem. 1981 Oct;90(4):1233–1236. doi: 10.1093/oxfordjournals.jbchem.a133578. [DOI] [PubMed] [Google Scholar]
  39. Unkrig C. J., Schröder R., Scharf R. E. Lorenzo's oil and lymphocytopenia. N Engl J Med. 1994 Feb 24;330(8):577–577. doi: 10.1056/NEJM199402243300819. [DOI] [PubMed] [Google Scholar]
  40. Uziel G., Bertini E., Bardelli P., Rimoldi M., Gambetti M. Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Dev Neurosci. 1991;13(4-5):274–279. doi: 10.1159/000112173. [DOI] [PubMed] [Google Scholar]
  41. Wade D. T., Collin C. The Barthel ADL Index: a standard measure of physical disability? Int Disabil Stud. 1988;10(2):64–67. doi: 10.3109/09638288809164105. [DOI] [PubMed] [Google Scholar]
  42. Wanders R. J., van Roermund C. W., van Wijland M. J., Nijenhuis A. A., Tromp A., Schutgens R. B., Brouwer-Kelder E. M., Schram A. W., Tager J. M., van den Bosch H. X-linked adrenoleukodystrophy: defective peroxisomal oxidation of very long chain fatty acids but not of very long chain fatty acyl-CoA esters. Clin Chim Acta. 1987 Jun 15;165(2-3):321–329. doi: 10.1016/0009-8981(87)90177-x. [DOI] [PubMed] [Google Scholar]
  43. Zierz S., Schröder R., Unkrig C. J. Thrombocytopenia induced by erucic acid therapy in patients with X-linked adrenoleukodystrophy. Clin Investig. 1993 Oct;71(10):802–805. doi: 10.1007/BF00190322. [DOI] [PubMed] [Google Scholar]
  44. Zinkham W. H., Kickler T., Borel J., Moser H. W. Lorenzo's oil and thrombocytopenia in patients with adrenoleukodystrophy. N Engl J Med. 1993 Apr 15;328(15):1126–1127. doi: 10.1056/NEJM199304153281513. [DOI] [PubMed] [Google Scholar]
  45. van Geel B. M., Assies J., Wanders R. J., Barth P. G. X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy. J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):4–14. doi: 10.1136/jnnp.63.1.4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. van Geel B. M., Assies J., Weverling G. J., Barth P. G. Predominance of the adrenomyeloneuropathy phenotype of X-linked adrenoleukodystrophy in The Netherlands: a survey of 30 kindreds. Neurology. 1994 Dec;44(12):2343–2346. doi: 10.1212/wnl.44.12.2343. [DOI] [PubMed] [Google Scholar]
  47. van Geel B. M., Koelman J. H., Barth P. G., Ongerboer de Visser B. W. Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. Neurology. 1996 Jan;46(1):112–118. doi: 10.1212/wnl.46.1.112. [DOI] [PubMed] [Google Scholar]
  48. van Swieten J. C., Koudstaal P. J., Visser M. C., Schouten H. J., van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988 May;19(5):604–607. doi: 10.1161/01.str.19.5.604. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES